A Phase 3 interventional study of Meloxicam and Glucosamine and Meloxicam in Osteoarthritis, sponsored by Zodiac Produtos Farmaceuticos S.A.. Status unknown. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-05-19.
Sponsored by Zodiac Produtos Farmaceuticos S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing glucosamine in Osteoarthritis — none open to participants now, none under way, none of them phase 3. Glucosamine · Osteoarthritis.
Among the 10 studies testing glucosamine in Osteoarthritis, this one is the 2nd largest by planned enrollment, is the only one that started in 2015, is one of 4 in phase 3, and was the 8th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.
Browse Osteoarthritis studies →None of the 10 studies testing glucosamine in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 375 is above the median of 80 across 2,239 interventional studies indexed under Osteoarthritis.
Median enrollment 221 across the 10 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 9 most frequent:
Zodiac Produtos Farmaceuticos S.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Zodiac Produtos Farmaceuticos S.A. has 2 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing glucosamine in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase III Study, double-blind, comparing association of anti-inflammatory and anti-rheumatic in 375 subjects with knee osteoarthritis.
Evaluation after 12 weeks of treatment, in 3 arms, the efficacy and safety of the association.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet
Drug: Meloxicam and Glucosamine
One tablet of meloxicam and one sachet of placebo once per day for 12 weeks
Drug: Meloxicam
One sachet of glucosamine and one tablet placebo once a day for 12 weeks
Drug: Glucosamine
Drug pages: Meloxicam · Glucosamine
Experimental
Also known as: Association Anti-inflamatory/Anti-rheumatic
Active Comparator
Also known as: Anti-inflamatory/Placebo
Active Comparator
Also known as: Anti-rheumatic/Placebo
Efficacy measured by decrease in score algofunctional Lequesne index after 12 weeks from the start of treatment
Decrease in score of algofunctional Lequesne index after 12 weeks from the start of treatment
Time frame: 12 weeks
Safety measured by frequency of adverse event
Safety as measured by total frequency of adverse event during the 12 weeks of treatment
Time frame: 12 weeks
No study locations are listed for this record.
The record gives a start of Jul 2015, a primary completion of Jun 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Meloxicam · Glucosamine
Zodiac Produtos Farmaceuticos S.A.